Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dynamix Pharmaceuticals Ltd.

Latest From Dynamix Pharmaceuticals Ltd.

Dynamix Pharmaceuticals Inc.

Optimization of a lead drug candidate often takes a few years, as companies assess hundreds and sometimes thousands of compounds, seeking just one with the best overall pharmacological profile. By contrast, Dynamix Pharmaceuticals Ltd. says its structure-based discovery approach dubbed DynamixFit has let the firm select lead molecules with less than 100 compounds synthesized in under two years. Dynamix aims to apply its techniques on two main tracks: first, to discover drug candidates that intervene with the metabolism of cancer cells; and second, to selectively target specific cellular signaling pathways mediated by Type II kinase inhibitors.

Biotechs Target Cancer Metabolism

As reseachers uncover linkages between tumor formation and cellular metabolism, start-ups and their venture backers see an opportunity to create a new class of cancer medicines. In this issue, we profile Advanced Cancer Therapeutics, Cornerstone Pharmaceuticals and Dynamix Pharmaceuticals.
BioPharmaceutical Business Strategies

Start-Up Previews (09/2010)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Biotechs Target Cancer Metabolism," features profiles of Advanced Cancer Therapeutics, Cornerstone Pharmaceuticals and Dynamix Pharmaceuticals. Plus these Start-Ups Across Health Care: AlloCure, ArisGen, HistoSonics and NeuraviBiotechnology.
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Inflammation
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • Dynamix Pharmaceuticals Ltd.
  • Senior Management
  • Oren M Becker, PhD, Pres. & CEO
    Yossi Bar-On, CFO
    Ofer Shpilberg, PhD, Dir., Clinical Rsch.
  • Contact Info
  • Dynamix Pharmaceuticals Ltd.
    Phone: (972) 8-9396010
    13 Gad Feinstein Rd., 3rd Fl., Ste. 308